1 completed, 1 suspended, 1 terminated. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Terminated 1 |
| Phase 2 | 1 | Suspended 1 |
Follow IRX4204: new trials by email Literature Review of IRX4204 trials Research Report on IRX4204
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Safety and Efficacy of IRX4204 in Mild to Moderate Plaque Psoriasis IRX4204, Placebo - Psoriasis, Plaque Type Psorisis | Phase 2 | Suspended | Io Therapeutics | 20 | 2027-03-01 | 2026-11-12 |
| Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLC IRX4204, erlotinib - Lung Cancer, Nonsmall Cell | Phase 1 | Terminated | Io Therapeutics | 12 | 2016-12-07 | 2025-05-14 |
| Study of IRX4204 for Treatment of Early Parkinson's Disease IRX4204 - Parkinson's Disease | Phase 1 | Completed | Io Therapeutics | 15 | 2014-08-01 | 2015-05-12 |
Carcinoma, Non-Small-Cell Lung (1) · Parkinson Disease (1) · Plaque, Amyloid (1) · Psoriasis (1)
Io Therapeutics (3)
United States (3)
Ken Marek, MD (1) · Martin E Sanders, MD (1)